{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T10:40:02Z","timestamp":1746268802637,"version":"3.40.4"},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.1744","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T12:43:02Z","timestamp":1402922582000},"page":"1283-1289","source":"Crossref","is-referenced-by-count":4,"title":["Type 2 Diabetes Mellitus Complicated by Hypertension in Japanese Patients: Switching Treatment from High-dose Angiotensin II Receptor Blockers to Losartan Plus Hydrochlorothiazide"],"prefix":"10.2169","volume":"53","author":[{"given":"Sunao","family":"Yamamoto","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Mori","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Nishida","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Uriu","sequence":"additional","affiliation":[{"name":"Nakama Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375: 2215-2222, 2010."},{"key":"2","unstructured":"2. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension 57: 891-897, 2011."},{"key":"3","unstructured":"3. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755-1762, 1998."},{"key":"4","unstructured":"4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 317: 703-713, 1998."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32: 3-107, 2009.","DOI":"10.1038\/hr.2009.34"},{"key":"6","unstructured":"6. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34: 2159-2219, 2013."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care 37: S14-S80, 2014.","DOI":"10.2337\/dc14-S014"},{"key":"8","unstructured":"8. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 3: 39-40, 2012."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"10","unstructured":"10. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003, 2002."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252: 726-732, 1990.","DOI":"10.1016\/S0022-3565(25)19986-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lijnen P, Fagard R, Staessen J, Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 12: 387-392, 1981.","DOI":"10.1111\/j.1365-2125.1981.tb01231.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res 26: 521-525, 2003.","DOI":"10.1291\/hypres.26.521"},{"key":"14","unstructured":"14. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 297: 319-328, 1988."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kimura G. Kidney and circadian blood pressure rhythm. Hypertension 51: 827-828, 2008.","DOI":"10.1161\/HYPERTENSIONAHA.108.110213"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Saito F, Kimura G. Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship. Hypertension 27: 914-918, 1996.","DOI":"10.1161\/01.HYP.27.4.914"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan--a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 73: 198-204, 2006.","DOI":"10.1016\/j.diabres.2006.01.013"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 300: 975-978, 1990.","DOI":"10.1136\/bmj.300.6730.975"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 21: 1157-1162, 2008.","DOI":"10.1038\/ajh.2008.245"},{"key":"20","unstructured":"20. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48: 219-224, 2006."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Racine N, Hamet P, Sampalis JS, Longo N, Bastien N. A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. J Hum Hypertens 24: 739-748, 2010.","DOI":"10.1038\/jhh.2010.3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Itoh H. Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. Hypertens Res 32: 1143-1147, 2009.","DOI":"10.1038\/hr.2009.162"},{"key":"23","unstructured":"23. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 73: 1303-1309, 2008."},{"key":"24","unstructured":"24. Matsui Y, Eguchi K, Ishikawa J, Shimada K, Kario K. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker. Am J Hypertens 24: 466-473, 2011."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 56: 77-85, 2010.","DOI":"10.1016\/j.jacc.2010.02.046"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N Engl J Med 359: 1565-1576, 2008.","DOI":"10.1056\/NEJMoa0806359"},{"key":"27","unstructured":"27. Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130\/80 mmHg: the azelnidipine and temocapril in hypertensive patients with Type 2 diabetes (ATTEST) study. Hypertens Res 31: 1499-1508, 2008."},{"key":"28","unstructured":"28. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120: 713-719, 2007."},{"key":"29","unstructured":"29. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829-840, 2007."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/12\/53_53.1744\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T10:20:48Z","timestamp":1746267648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/12\/53_53.1744\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.1744","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2014]]}}}